Phaseline

Targets › ALOX5AP

ALOX5AP (Arachidonate 5-lipoxygenase-activating protein): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Cardiovascular; next expected readout Dec 2026.

Required for leukotriene biosynthesis by ALOX5 (5-lipoxygenase). Anchors ALOX5 to the membrane. (UniProt, P20292)

Open in Phaseline: the race on ALOX5AP, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
KardiganTonlamarsen
Antisense oligonucleotide targeting ALOX5AP; reduces leukotriene production to lower blood
ALOX5APPhase 2HypertensionDec 2026

Conditions

Hypertension (1)

Modalities

other (1)

Companies

Kardigan (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.